Foralumab is under clinical development by Tiziana Life Sciences and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase III drugs for Secondary Progressive Multiple Sclerosis (SPMS) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Foralumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Foralumab is under development for the treatment of primary progressive multiple sclerosis, type I diabetes, Crohn's disease, non-alcoholic steatohepatitis (NASH), Alzheimer's disease, secondary progressive multiple sclerosis. It can be administered through nasal, oral, subcutaneous and intravenous infusion. The drug candidate acts by targeting the CD3 antigen.
The drug was also under development for the treatment of non alcoholic fatty liver disease (NAFLD), type 2 diabetes and acute cellular renal allograft rejection, primary biliary cirrhosis (primary biliary cholangitis (PBC)), amyotrophic lateral sclerosis and traumatic brain injury.
The drug candidate was also under development for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and pulmonary inflammation. It is administered through nasal route.
Tiziana Life Sciences overview
Tiziana Life Sciences Ltd (Tiziana), formerly Tiziana Life Sciences, is a clinical-stage biotechnology company that discovers and develops drugs to treat inflammatory diseases and cancers. Its lead product candidate, Milciclib (TZLS-201), intended for the treatment of thymic carcinoma. The company’s other clinical programs includes Foralumab (TZLS-401), a human engineered anti-human CD3 antibody intended for the treatment of Crohn’s disease and Nonalcoholic steatohepatitis. The company’s preclinical stage candidates include anti-IL6R (TZLS-501), a fully human anti-IL-6R monoclonal antibody targeting the interleukin-6 receptor. Tiziana is headquartered in Hamilton, Bermuda, the UK.
For a complete picture of Foralumab’s drug-specific PTSR and LoA scores, buy the report here.